MedTrace Logo

Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine

NCT05042635 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-13

No results posted yet for this study

Summary

The purpose of this study is to objectively and standardly evaluate the clinical efficacy and safety of sequential treatment of psoriasis with traditional Chinese and Western medicine through a multi-center, randomized, double-blind, placebo-controlled trial.

Conditions

Interventions

DRUG

Ixekizumab+Jueyin Granules

Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once). Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.

DRUG

Ixekizumab+Jueyin placebo Granules

Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once). Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.

Sponsors & Collaborators

  • Shanghai Skin Disease and Venereal Disease Hospital

    collaborator OTHER

  • Shanghai Yueyang Integrated Medicine Hospital

    lead OTHER

Principal Investigators

  • Bin Li · Shanghai Skin Disease Hospital, School of Medicine, Tongji University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2024-09-30
Completion
2024-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05042635 on ClinicalTrials.gov